scholarly journals Predictive factors of rapid linear renal progression and mortality in patients with chronic kidney disease

2020 ◽  
Vol 21 (1) ◽  
Author(s):  
Ibrahim Ali ◽  
Rajkumar Chinnadurai ◽  
Sara T. Ibrahim ◽  
Darren Green ◽  
Philip A. Kalra
2021 ◽  
Vol 6 (14) ◽  
pp. 80-88
Author(s):  
Huseyin Duru ◽  
Ekrem KARA

Objective: To evaluate the effect of 24 hour systolic blood pressure (SBP) and diastolic blood pressure (DBP) variability (BPV) on renal progression in hypertensive patients with chronic kidney disease (CKD) Methods: A total 59 hypertensive patients (mean age: 54.2±14.6 years, 50.8% male) with CKD who underwent 24 hours ambulatory blood pressure measurement (ABPM) were included. Data on SBP, DBP, BPV coefficients (VC) for SBP (SBP-CV) and DBP (DBP-CV) were recorded. A decrease in e-GFR of <5 ml/min/year was considered as normal renal progression and a decrease in ≥5 ml/min/year was considered as rapid renal progression. Results: Overall, 40.6% of the patients had uncontrolled HT, while 45.8% had non-dipper pattern. Mean±SD daytime and night-time SBP and SBP-VC values were 135.3±17.9 mmHg, 128.6±23.0 mmHg, 11.7±2.8 and 9.5±3.6, respectively. Mean±SD daytime and nigh-time DBP and DBP-VC values were 84.5±13.4 mmHg, 77.2±16.1 mmHg, 13.8±3.8 and 12.0±3.7, respectively. Rapid renal progression was detected in 25.4% of patients with no significant difference in daytime, night-time and total SBP, SBP-VC, DBP and DBP-VC values between patients with rapid vs. natural renal progression. The regression analysis adjusted for age, gender, presence of DM, baseline e-GFR and dipping status revealed no significant impact of SBP-VC and DBP-VC in predicting rapid progression (p> 0.05). Conclusion: In conclusion, our finding revealed no significant association between BPV and renal progression in hypertensive patients with CKD. Larger scale prospective, randomized controlled trials with longer follow-up are needed to clarify this issue.


2020 ◽  
Vol 9 (5) ◽  
pp. 1346
Author(s):  
Maria Antonietta Barbieri ◽  
Michelangelo Rottura ◽  
Giuseppe Cicala ◽  
Rossella Mandraffino ◽  
Sebastiano Marino ◽  
...  

Nephrotoxic drugs prescriptions are often prescribed inappropriately by general practitioners (GPs), increasing the risk of chronic kidney disease (CKD). The aim of this study was to detect inappropriate prescriptions in patients with CKD and to identify their predictive factors. A retrospective study on patients with creatinine values recorded in the period 2014–2016 followed by 10 GPs was performed. The estimated glomerular filtration rate (eGFR) was used to identify CKD patients. The demographic and clinical characteristics and drugs prescriptions were collected. A descriptive analysis was conducted to compare the characteristics and logistic regression models to estimate the predictive factors of inappropriate prescriptions. Of 4098 patients with creatinine values recorded, 21.9% had an eGFR <60 mL/min/1.73 m2. Further, 56.8% received inappropriate prescriptions, with a significantly lower probability in subjects with at least a nephrologist visit (Adj OR 0.54 (95% CI 0.36–0.81)) and a greater probability in patients treated with more active substances (1.10 (1.08–1.12)), affected by more comorbidities (1.14 (1.06–1.230)), or with serious CKD (G4/G5 21.28 (7.36–61.57)). Nonsteroidal anti-inflammatory drugs (NSAIDs) were the most used contraindicated drugs (48.5%), while acetylsalicylic acid was the most inappropriately prescribed (39.5%). Our results highlight the inappropriate prescriptions for CKD authorized by GPs and underline the need of strategies to improve prescribing patterns.


Medicine ◽  
2016 ◽  
Vol 95 (30) ◽  
pp. e4203 ◽  
Author(s):  
Po-Ya Chang ◽  
Li-Nien Chien ◽  
Yuh-Feng Lin ◽  
Mai-Szu Wu ◽  
Wen-Ta Chiu ◽  
...  

2018 ◽  
Vol 33 (suppl_1) ◽  
pp. i137-i137
Author(s):  
Seung Don Baek ◽  
Mun Jang ◽  
Wonhak Kim ◽  
Eun Kyoung Lee ◽  
So Mi Kim ◽  
...  

2015 ◽  
Vol 61 (6) ◽  
pp. 195S
Author(s):  
Marcos K. Lau ◽  
Joy L. Meier ◽  
Warren Gasper ◽  
David H. Lovett ◽  
Pauline M. Velez ◽  
...  

Renal Failure ◽  
2012 ◽  
Vol 34 (2) ◽  
pp. 165-170 ◽  
Author(s):  
Siren Sezer ◽  
Şebnem Karakan ◽  
Nurhan Özdemir Acar

2015 ◽  
Vol 20 (5) ◽  
pp. 740-747 ◽  
Author(s):  
Nao Nohara ◽  
Hiroaki Io ◽  
Mayumi Matsumoto ◽  
Masako Furukawa ◽  
Kozue Okumura ◽  
...  

2020 ◽  
Vol 15 ◽  
pp. 117727192097614
Author(s):  
Ibrahim Ali ◽  
Sara T Ibrahim ◽  
Rajkumar Chinnadurai ◽  
Darren Green ◽  
Maarten Taal ◽  
...  

Biomarker discovery in the field of risk prediction in chronic kidney disease (CKD) embraces the prospect of improving our ability to risk stratify future adverse outcomes and thereby guide patient care in a new era of personalised medicine. However, many studies that report biomarkers predictive of CKD progression share a key methodological limitation: failure to characterise patients’ renal progression precisely. This weakens any observable association between a biomarker and an outcome poorly defined by a patient’s change in renal function over time. In this commentary, we discuss the need for a better approach in this research arena and describe a compelling strategy that has the advantage of offering robust and meaningful biomarker exploration relevant to CKD progression.


Sign in / Sign up

Export Citation Format

Share Document